Stay informed with the latest litigation news. Explore now

IP Verse

Fibrogen competitive analysis

Latest publications and patents of Fibrogen New

Explore the latest publications and patents granted to Fibrogen, showcasing their recent innovations and technological advancements.

Last updated on: Sep 6, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Fibrogen

EP2298301
Nov 16, 2022Medicaments For Increasing Endogenous Erythropoietin (Epo)Patent Maintained As Amended
EP3470397
Dec 29, 2021Crystalline Forms Of A Prolyl Hydroxylase InhibitorGranted And Under Opposition
EP3003284
Feb 12, 2020Pharmaceutical Formulations Of A Hif Hydroxylase InhibitorGranted And Under Opposition
EP2324834
May 8, 2019Methods Of Increasing Endogenous Erythropoietin (Epo)Revoked
EP2872488
Aug 22, 2018Crystalline Forms Of A Prolyl Hydroxylase InhibitorRevoked
EP2289531
Jul 4, 2018Medicaments For Increasing Endogenous Erythropoietine (Epo)Granted And Under Opposition
EP2322153
Oct 8, 2014Use Of Hif Alpha Stabilizers For Enhancing ErythropoiesisRevoked

Latest oppositions filed by Fibrogen

Explore patent oppositions filed by Fibrogen against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3357911
Prolyl Hydroxylase Inhibitors And Methods Of UseAKEBIA THERAPEUTICSFeb 13, 2023

Latest patents of Fibrogen opposed by its competitors

Explore Fibrogen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2298301
Nov 16, 2022Medicaments For Increasing Endogenous Erythropoietin (Epo)1
EP3470397
Dec 29, 2021Crystalline Forms Of A Prolyl Hydroxylase Inhibitor3
EP3003284
Feb 12, 2020Pharmaceutical Formulations Of A Hif Hydroxylase Inhibitor2
EP2324834
May 8, 2019Methods Of Increasing Endogenous Erythropoietin (Epo)1
EP2872488
Aug 22, 2018Crystalline Forms Of A Prolyl Hydroxylase Inhibitor3
EP2289531
Jul 4, 2018Medicaments For Increasing Endogenous Erythropoietine (Epo)2
EP2322153
Oct 8, 2014Use Of Hif Alpha Stabilizers For Enhancing Erythropoiesis4

Latest PTAB cases involving Fibrogen New

Discover the latest PTAB cases involving Fibrogen, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 12, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Fibrogen

IPR2016-01323Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01322Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01320Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01319Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01318Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01315Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied

Top competitors of Fibrogen

Top competitors of Fibrogen based on patent oppositions.